KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 20925 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
EMPIRE (NSABP FC-13): a biomarker-driven phase II platform trial evaluating cemiplimab-based immunotherapy in microsatellite-stable colorectal cancer with ctDNA-defined minimal residual disease. PMID 42345857 · Future Oncol · 2026-Jul 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Model-Informed Development of a Subcutaneous Formulation of Tislelizumab: Phase 1 Pharmacokinetics in Patients With Cancer. PMID 42337921 · Clin Transl Sci · 2026-Jul The record describes a Phase I PK study with PopPK modeling and simulations to support Phase 3 dose selection. While it is a randomized, drug-intervention oncology study, it reports only pharmacokinetic outcomes (bioavailability, exposure), not time-to-event efficacy endpoints like OS or PFS with Kaplan-Meier or HR. Therefore, it does not meet the core requirement for a time-to-event efficacy endpoint.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Sebetralstat for on-demand treatment of hereditary angioedema: A pooled analysis of placebo-controlled clinical trials. PMID 42318595 · World Allergy Organ J · 2026-Jul 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Off-Protocol Radiotherapy in Prospective Systemic Therapy Trials for Metastatic Non-Small Cell Lung Cancer. PMID 42314501 · Clin Lung Cancer · 2026-Jul The record is a methodological review/meta-analysis of systemic therapy trial protocols, not an original report of trial results. It does not present any primary or secondary time-to-event efficacy data (e.g., OS, PFS, Kaplan-Meier curves, HR) from a randomized trial.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Safety and efficacy of levacetylleucine in ataxia-telangiectasia: a phase 3, randomised, double-blind, placebo-controlled crossover trial. PMID 42309084 · Lancet Neurol · 2026-Jul 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Patient-reported outcomes in BRUIN CLL-321: A randomized phase 3 trial comparing pirtobrutinib to investigators choice of idelalisib plus rituximab or bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the post-cBTKi setting. PMID 42308688 · J Geriatr Oncol · 2026-Jul 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
β-Blockers after myocardial infarction with preserved or mildly reduced left ventricular ejection fraction: Fragility of contemporary evidence. PMID 42306649 · Am Heart J Plus · 2026-Jul 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial. PMID 42296979 · Lancet Oncol · 2026-Jul 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Phase II Trial of First-Line Durvalumab and Chemotherapy in Patients With Extra-Pulmonary Small Cell Carcinoma. PMID 42293288 · JTO Clin Res Rep · 2026-Jul 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in patients with high body mass index or diabetes mellitus. PMID 42284622 · ESMO Open · 2026-Jul 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
L S B
旧组与严格 v3 交集 eligiblephase3_publication_type confirmed 2 Figure · 4 Panel · risk visible
First-line ET plus palbociclib versus standard mono-chemotherapy in high-risk HR-positive/HER2-negative metastatic breast cancer and indication for chemotherapy: primary results from the randomized phase IV PADMA study. PMID 42275799 · ESMO Open · 2026-Jul The study is a randomized Phase IV trial, which does not meet the inclusion criterion for Phase III/IIIb or Phase II/III trials.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effect of [68Ga]Ga-PSMA-11 PET-CT in the diagnosis of prostate cancer in men with equivocal or clinically high-risk non-suspicious findings on multiparametric MRI (PRIMARY2): a multicentre, non-inferiority, phase 3, randomised controlled trial. PMID 42269655 · Lancet Oncol · 2026-Jul The trial is a Phase 3 randomized controlled trial in prostate cancer with original results, but the intervention is a diagnostic imaging agent ([68Ga]Ga-PSMA-11 PET-CT) and the primary endpoints are diagnostic accuracy and biopsy avoidance, not a time-to-event efficacy endpoint like OS or PFS. Therefore, it does not meet the inclusion criteria.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Psychometric evaluation of the NFOSI-18 disease related symptoms - Physical, NFOSI-18 Total, and FACT GP5 in the recurrent ovarian cancer phase III study GY004. PMID 42258989 · Gynecol Oncol · 2026-Jul The record describes a psychometric evaluation of patient-reported outcome measures (quality-of-life instruments) from a Phase III randomized trial in oncology. While it originates from an eligible trial type, the report itself is a secondary, quality-of-life analysis focusing on instrument validation, not a report of the trial's primary or key secondary time-to-event efficacy results (e.g., OS, PFS). Therefore, it is excluded as a quality-of-life-only report.
L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Progression-free Survival Following Primary Staging with [18F]PSMA-1007-PET/ceCT Versus Na[18F]F-PET/ceCT in Prostate Cancer: Results from the PRISMA-PET Randomized Controlled Trial. PMID 42255253 · Eur Urol Open Sci · 2026-Jul The study is a randomized oncology trial with PFS as a primary endpoint, but it lacks a drug-containing intervention (comparing imaging tracers) and does not explicitly state the trial phase as Phase III or definitive.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
HTD1801 in Combination with Metformin for Type 2 Diabetes. PMID 42251702 · NEJM Evid · 2026-Jul 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
SOHO State of the Art Updates and Next Questions | Early Stage Hodgkin Lymphoma-Are We Ready for Novel Agents? PMID 42242960 · Clin Lymphoma Myeloma Leuk · 2026-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Secukinumab for Giant Cell Arteritis. PMID 42234457 · NEJM Evid · 2026-Jul 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Guselkumab Safety in Patients With Latent Tuberculosis: Analysis of 11 Studies in Psoriatic Disease. PMID 42226468 · J Dermatol · 2026-Jul The study is a safety analysis of a drug (guselkumab) in psoriatic disease, not a human malignant neoplasm (oncology) trial. It reports on safety outcomes (TB reactivation, liver enzyme elevations) and does not include a primary or key secondary time-to-event efficacy endpoint such as OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier curve, or hazard ratio for such outcomes.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Response to Letter to the Editor: "Efficacy and Safety of Combination Therapy With Low Dose of Telmisartan and S-Amlodipine in Patients With Hypertension: A Randomized, Double-Blind, Multicenter, Therapeutic Confirmatory, Phase III Clinical Trial". PMID 42215366 · Clin Ther · 2026-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Efficacy and safety of subcutaneous and intravenous administration of atezolizumab in patients with non-small cell lung cancer, including early-stage, locally advanced or metastatic disease: Updated results of the IMscin001 and IMscin002 randomized studies. PMID 42214243 · Lung Cancer · 2026-Jul 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Sparsentan Versus Irbesartan in Pediatric Patients With FSGS. PMID 42210914 · Kidney Int Rep · 2026-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Secondary Analysis of the CAN-Study, a Randomised Controlled Trial - Local Anaesthesia and Overall Survival. PMID 42210709 · Acta Anaesthesiol Scand · 2026-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Trial protocol: RadTARGET, a multicenter phase II randomized controlled trial evaluating focal radiotherapy boost with de-intensification of dose to non-suspicious prostate in patients with intermediate- or high-risk prostate cancer. PMID 42205730 · Clin Transl Radiat Oncol · 2026-Jul 方案论文未报告临床试验结果。
H S B
严格 v3 独有 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Complementary evaluation of phase III immunotherapy trials in advanced HCC using the survival-inferred fragility index. PMID 42203603 · Dig Liver Dis · 2026-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Adjuvant chemoradiotherapy versus completion total mesorectal excision after local excision for early rectal cancer (TESAR): a multicentre, randomised, controlled, phase 3, non-inferiority trial. PMID 42202843 · Lancet Gastroenterol Hepatol · 2026-Jul 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Efficacy translation between phase II and phase III trials in gynecologic oncology: a cross-phase meta-comparative analysis. PMID 42202504 · Int J Gynecol Cancer · 2026-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Molecular classification and association with survival outcomes in high-intermediate and high-risk early-stage endometrial cancers: Ancillary analysis of GOG-0249. PMID 42190623 · Gynecol Oncol · 2026-Jul The report is an ancillary biomarker analysis of a randomized trial. While it meets many criteria (oncology, human, randomized, drug intervention, time-to-event endpoints), the specific requirement for an original formal result report of a Phase III/IIIb or Phase II/III trial with a drug intervention is not met. The phase is not explicitly established in the provided text, and the report's primary focus is prognostic biomarker classification rather than the primary efficacy comparison of the drug intervention vs. control.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The CHRONO trial: Protocol for a randomized controlled trial of early time-restricted eating in patients with breast or rectal cancer. PMID 42190452 · Nutr Res · 2026-Jul 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real-World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial. PMID 42175630 · J Gastroenterol Hepatol · 2026-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Study outcome and journal impact factor: a meta-epidemiologic analysis of phase III gynecologic oncology trials. PMID 42172953 · Int J Gynecol Cancer · 2026-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Description of the Tranquillo Phase 3 Clinical Trial Designs/Study Protocols to Assess Ritlecitinib in Adults and Adolescents with Nonsegmental Vitiligo. PMID 42171987 · Dermatol Ther (Heidelb) · 2026-Jul 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Lenvatinib plus pembrolizumab in participants with advanced or recurrent endometrial cancer: Study 309/KEYNOTE-775 and ENGOT-en9/LEAP-001 post-(neo)adjuvant therapy outcomes. PMID 42167105 · Int J Gynecol Cancer · 2026-Jul 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Long-term oncological and reproductive outcomes following treatment with the levonorgestrel intra-uterine device for endometrial hyperplasia and adenocarcinoma: results from the feMMe phase 2 randomized clinical trial. PMID 42167104 · Int J Gynecol Cancer · 2026-Jul 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Bladder Adjuvant Radiotherapy: Phase III Multicenter Randomized Controlled Trial of Adjuvant Radiotherapy or Observation for Postcystectomy Muscle-Invasive Bladder Cancer. PMID 42166701 · J Clin Oncol · 2026-Jul 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Efficacy and Safety of SPH3127 Tablet, a Novel Direct Renin Inhibitor, in Patients with Mild-to-Moderate Essential Hypertension: A Phase III Randomised Trial. PMID 42165988 · Drugs · 2026-Jul 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Fosfomycin versus ciprofloxacin for febrile neutropenia prophylaxis in high-risk haematological patients (FOVOCIP): a phase 3, open-label, multicentre, randomised, non-inferiority trial. PMID 42164340 · Lancet Reg Health Eur · 2026-Jul 未发现恶性肿瘤人群证据。
H B
仅广召回影子组 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Multimodal prehabilitation in patients with advanced ovarian cancer. PMID 42155563 · Gynecol Oncol · 2026-Jul The trial is oncology-focused, human, and randomized, but it does not meet all required criteria: the phase is not specified as Phase III or IIIb, the intervention is multimodal prehabilitation (non-drug), and the primary endpoint is functional capacity (6MWT), not a time-to-event efficacy endpoint (OS, PFS, etc.).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effect of comprehensive geriatric assessment and supportive care on quality of life in older patients with cancer receiving curative treatment: The GOSPEL randomised controlled trial. PMID 42155314 · J Geriatr Oncol · 2026-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
[Oligometastatic hormone-sensitive prostate cancer: when can less be more?]. PMID 42151597 · Urologie · 2026-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Minimal Systemic Exposure with Maximal Delgocitinib Cream Use in Patients with Severe Chronic Hand Eczema in the DELTA 2 Randomized, Vehicle-Controlled, Double-Blind, Phase 3 Trial. PMID 42143645 · Dermatol Ther (Heidelb) · 2026-Jul 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
OLIGOPELVIS 2-GETUG P12- elective nodal radiotherapy for oligorecurrent pelvic/para-aortic nodes in prostate cancer: early toxicity of a randomized phase 3 trial. PMID 42140755 · Radiother Oncol · 2026-Jul The study is a randomized phase III oncology trial with a drug intervention (iADT), but its primary reported outcome is 18-month toxicity, not a time-to-event efficacy endpoint (e.g., OS, PFS, DFS) required for inclusion.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Response to the letter to the editor by Pontoriero et al. regarding the article "Cost-utility-analysis of molecular-integrated-profile for women with (high)intermediate risk endometrial cancer - PORTEC-4a an international randomised phase 3 trial by Van den Heerik et al.". PMID 42128303 · Radiother Oncol · 2026-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Improved assessment of coronary artery disease in obese patients with flurpiridaz-18F positron emission tomography myocardial perfusion imaging: A prespecified subgroup analysis of the AURORA phase 3 study. PMID 42128226 · J Nucl Cardiol · 2026-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Final overall survival analysis of the APPLE study: atezolizumab and platinum-pemetrexed with or without bevacizumab for metastatic nonsquamous non-small cell lung cancer. PMID 42127535 · Lung Cancer · 2026-Jul 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. PMID 42120723 · Nat Med · 2026-Jul 未发现恶性肿瘤人群证据。
L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Mirikizumab as Induction and Maintenance Therapy in Chinese Patients with Ulcerative Colitis: A Subpopulation Analysis of the Randomized, Global Phase 3 LUCENT-1 and LUCENT-2 Trials. PMID 42120652 · BioDrugs · 2026-Jul 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Whole blood transcriptome profiling in patients treated with deucravacitinib and novel mechanistic insights into TYK2 inhibition in lupus: results from a post hoc analysis of the PAISLEY SLE phase 2 trial. PMID 42115051 · Ann Rheum Dis · 2026-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Concurrent Versus Sequential Radiation Dose Escalation to the Surgical Cavity for Conservative Treatment of High-Risk Early Breast Cancer: NRG/RTOG 1005 Phase III Trial. PMID 42114027 · J Clin Oncol · 2026-Jul The study is an eligible Phase III randomized trial with a time-to-event efficacy endpoint, but it does not involve a drug-containing intervention as required. Both arms involve radiation therapy protocols (sequential vs. concurrent boost), with no systemic drug therapy described in the intervention.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Biopsy with same-session MRI-guided laser interstitial thermal therapy versus biopsy alone in patients with primary unresectable glioblastoma: a multicentre randomised controlled trial. PMID 42112495 · Lancet Reg Health Eur · 2026-Jul The record is a randomized trial for human glioblastoma with an OS endpoint, but the intervention is a procedure (LITT) and not a drug, and the phase is not established as Phase III/IIIb or Phase II/III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Rilzabrutinib for persistent or chronic immune thrombocytopenia (ITP): a Bruton tyrosine kinase inhibitor that can target multiple pathophysiological pathways. PMID 42106923 · Expert Rev Hematol · 2026-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -